

Curriculum Vitae
Christopher M. Reilly

Current Position

Department Chairman for Biomedical Sciences
Virginia College of Osteopathic Medicine and
Research Associate Professor Virginia Technical Institute and State University
2265 Kraft Drive
Blacksburg, VA 24060
Ph (540) 231-9365
e-mail: chreilly@vcom.vt.edu

Education

College	University of New Mexico, 1991, Biology
Graduate School	Medical College of Georgia, 1997, Ph.D. Department of Physiology and Endocrinology
Postdoctorate	Postdoctoral fellowship, Medical University of South Carolina Department of Medicine/Division of Rheumatology 1997-2000

Employment

2000-2002 Research Assistant Professor, Division of Rheumatology, Department of Medicine, Medical University of South Carolina, Charleston, SC

2002-2005; Assistant Professor and Chair for Physiology, Edward Via Virginia College of Osteopathic Medicine, Blacksburg, VA

2005-2007; Associate Professor and Chair for Physiology, Edward Via Virginia College of Osteopathic Medicine, Blacksburg, VA

2007-2012; Associate Professor and Chair for Physiology and Biochemistry, Edward Via Virginia College of Osteopathic Medicine, Blacksburg, VA

2012-2022; Tenured Professor and Chair for Physiology and Biochemistry, Edward Via Virginia College of Osteopathic Medicine, Blacksburg, VA (awarded tenure 2012)

2022-Present Chairman for Biomedical Sciences, Edward Via Virginia College of Osteopathic Medicine, Blacksburg, VA

2002-2008; Research Assistant Professor, Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA

2008-Present; Research Associate Professor, Department of Biomedical Sciences and Pathobiology, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg, VA

Experience and Professional Memberships

1997-present; member of FASEB

1997-present; American Association of Immunologists

1997-1998; steering committee member for the postdoctoral association at MUSC

1999-2001; Elected Present of the Post-doctoral Scholars association at MUSC

2002-present; Member of the Internal Association of Science Medical Educators
2002-SCORE Study Section, Grant Review Committee, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS-NIH)
2003-Present; Member of Department Chairs of Physiology
2004 NIH study section member (Gene targeting and bone remodeling)
2006-Present; Member of the American Physiological Society
2008 Arthritis Foundation Inflammation study section member
2009 Arthritis Foundation grant reviewer
2009 NIH challenge grant review
2009 Reviewer or American Osteopathic Association (AOA) abstracts for annual meeting
2009 NIH grant reviewer (Cellular and Molecular Biology of the Kidney Study Section (CMBK))
2010 Reviewer or AOA abstracts for annual meeting
2011 Reviewer or AOA abstracts for annual meeting
2011 NIH NCCAM PK20 Education panel grant review panel
2010-present Editorial board IRSN Rheumatology
2012 Reviewer or AOA abstracts for annual meeting
2012 Reviewer for AOA grants
2012 NIH NCCAM PK20 Education panel grant review panel
2013 Reviewer for AOA abstracts for annual meeting
2014 Reviewer for AOA proposals for funding
2014 Reviewer for DoD lupus pre awards study section
2015 Reviewer for AOA grant applications
2015 AOA poster reviewer for AACOM national meeting
2015 NIH tandem study sections F07-S20L, IMM-S81A
2015 Reviewer for DoD Allergy and Immunology study section
2016 NIH ZL-I (M1) 1NIAID Investigator Initiated Program Project Applications
2016 NIH study section ZRG1 IMM-T AREA Review: Immunology
2016 NIH study section ZGR1 F07-T Fellowship: Immunology
2017 NIH ZL-I (M1) 1NIAID Investigator Initiated Program Project Applications
2018 NIAID peer review for Autoimmunity Centers of Excellence NIAID peer review for Autoimmunity Centers of Excellence (ACE).
2019/01 ZAI1 TC-I (J1) R
2019 NIH study section PPG proposals
2019 NIH NIAID study section P01 proposals
2019 DoD Lupus Research Program (grant reviewer) concept awards
2020 NIH NIAID P01 proposals
2021 NIH NIAID P01 proposals
2021 DoD Lupus Research Program (grant reviewer) concept awards
2021 NIH Acting Chair ZRG1 F07 Infectious diseases and Immunology Panel C

Editorial Board *Frontiers in Immunology* 2016- present

ad-hoc reviewer for many journals including: *The Journal of Immunology*, *Proceedings of the National Academy of Sciences*, *Clinical Immunology*, *Kidney International* and several others.

Awards

Recipient of the 2004 Hulda Irene award; awarded by the Arthritis Foundation for the "Outstanding Researcher of the Year."

Awarded the "Outstanding Researcher of the Year," by the Virginia College of Osteopathic Medicine 2003-2004

Nominated by the students at Virginia College of Osteopathic Medicine in 2006 for the National Northrup Award that recognizes "The Most Outstanding Medical Educator."
Awarded the "Outstanding Researcher of the Year," by the Virginia College of Osteopathic Medicine 2018-2019

Prior Funding

Medical College of Georgia NIH Training Grant; July 1996-July 1997

Title "Role of NO inhibition in lupus nephritis," (\$30,000)
Dean's Post Doctoral Research Fellowship Grant;
Medical University of South Carolina
Role: (PI) 7/1/1998-7/1/ 1999

Title "The effect of Prostaglandin J₂ on mesangial cell inflammation," (\$105,000)
Arthritis Foundation Post -doctoral Research Grant Award July 1999-July 2002.
Role: (PI) 7/1/1999-6/30/2001

Title "The use of PPAR- γ agonists to inhibit kidney inflammation," (\$25,000)
Research Enhancement Awards Grant, VA Medical Center
Role: (PI) 6/1/2000- 6/1/2001

Title "The role of adhesion molecules in lupus nephritis treated with AGIX-1096," (\$105,000)
Atherogenics Inc.
Role: (PI) 1/1/2000-1/1/2001

Title "Inhibition of lupus nephritis in IRF-1 deficient mice," Total Budget \$136,000.
NIH R21, National Institute of Arthritis and Musculoskeletal & Skin Diseases
Role: (PI) 2/15/03-6/31/05

Alliance for Lupus Research
Title "Histone deacetylase inhibitors are therapeutic targets in SLE." Total Budget \$1,000,000.
Role C0-PI, Nilamadhab Mishra PI, Wake Forest Medical School 2/01/03-1/31/07

Harvey Peters Foundation
Title "The mechanism of *Brucella* mediated reactive arthritis"
Total Budget 105,000
Role: (PI) 7/1/06-11/31/07

Arthritis Foundation, Arthritis Investigator Award
Title "IRF-1 deletion in MRL/lpr mice"
Total budget \$375,000.
Role: (PI) 7/1/04-6/30/10

NIH-R15, National Institute of Allergy and Infectious Diseases
Title "Inhibition of lupus nephritis with CeO₂ Nanoparticles"
Total Budget \$250,000
Role: (PI) 2/1/08 -2/1/11

NIH R03 National Institute of Allergy and Infectious Diseases
Title "micro RNA expression in lupus nephritis"

Total Budget \$158,000
Role (PI) 8/1/2010-7/31/12

Virginia Regional College of Veterinary Medicine (internal award)
Inhibition of anti-GBM disease

Total Budget \$20,000
Role (PI) 6/1/11-5-31-12

Virginia Regional College of Veterinary Medicine
T-32 training award (DVM training grant by NIH)
XJ Meng PI
Role Co-I.

NIH-R01 Prolonged Inhibition of Pathologic Neovascularization by Catalytic Antioxidants (\$2,608, 097)
PI James McGinnis (January 2012-January 2016)
Total award (\$2,608, 097)
Role Co-I Total (\$280,800 to CM Reilly 5% effort)

Alliance for Lupus Research-Investigator Award
PI Rujuan Dai (\$250,000 yr for up to 3 years) scheduled to begin March 2102
Role Co-I (3% effort)

NIH R15 National Institute of Arthritis and Musculoskeletal Diseases
Title "micro RNA expression in NZB/W mice"
Priority score 16
Total Budget \$485,000
Role (PI) 2/1/2013-1/31/16
Acetylon Pharmaceuticals:
Selective HDAC inhibitors for the treatment of SLE
Total budge \$242,000
Role (PI) 2/1/2-14-1/31/18

Current Funding

NIH R01 Mechanistic role of probiotic lactobacillus reuteri in autoimmune lupus
Xin Luo PI (4-1-2018-3-31-2022)
Role Co-I

NIH-R03 Effect of maternal immune factors in shaping the infant gut microbiota
Role PI 4/1/2016-3/31/2019 (NCE)

RILITE Foundation The effectiveness of a Bcl-6 inhibitor for the treatment of lupus nephritis.
\$29,000
Role PI 11/01/2019 – 10/31/2020

NIH/NIAID R15AI152022-01 Role: PI 4/1/2020 – 3/31/2023
Title: Selective HDAC6 inhibition decreases B cell activation in systemic lupus erythematosus
Effort: 10% Level of Funding: \$485,000
Grants Officer: Dr. Michael Minnicozzi 240-627-3532 minnicozzim@niai.nih.gov

Project Goals: The goal of the proposed research is to mechanistically define the role of HDAC6, on B cell activation in systemic lupus erythematosus. The results of this project are to gain a better understanding of how protein acetylation may effect glomerulonephritis.
Specific Aims: (1). Using a selective HDAC6 inhibitor, define how acetylation alters B cell differentiation and activation in lupus mice. (2) Define the mechanism of pharmacological inhibition of HDAC6 in NZB/W and BXSB/Yaa mice.

Teaching experience

1998-2001 Topics in Immunology, Medical University of South Carolina
1999- Guest lecturer in Medical Endocrinology at Ross Medical University
2000-Lecturer for Medical Endocrinology at Ross Medical University
2002-Present; course director and lecturer for Physiology at the Virginia College of Osteopathic Medicine
2002-present; special lectures in Immunology at the Veterinary School at Virginia Polytechnic Institute and State University

Currently teaching at VCOM

Pulmonology, endocrinology, renal physiology, hematology, and reproduction

Invited speaker:

Concurrent speaking session, American College of Rheumatology 2003, New Orleans, LA
VCOM research Day October 2004 (IRF-1 gene deletion in lupus nephritis)
VCOM research Day October 2005 (Histone deacetylase inhibitors as a treatment for lupus nephritis)
Sports Medicine seminar series for VCOM/VT
 January 2005 (Physiology and Training)
 March 2005 (Overtraining Syndrome)
 November 2005 (What the clinical should know about muscle training)
Arthritis Foundation
 April 2005 (State of the art treatment and therapy for arthritis)
 October 2005 (State of the art treatment and therapy for arthritis)
 February 2008 (Arthritis treatment and therapy)
Engineering department at Virginia Tech "Osteoarthritis and engineered matrices" 2006
Institute of Critical Thinking and Advanced Technologies, Virginia Tech 2008, "Glomerular Basement Disease in SLE."
East Carolina State University, Brody School of Medicine 2007. "The ups and down of Nitric Oxide."
VT-Topics In Immunology 2008, 2009, 2010, 2011.
Medical University of South Carolina-Invited speaker, January 2012. "SLE Beyond Genetics."
Controversies in Rheumatology Meeting Budapest, Hungary March 2012 "HDACi to treat SLE."
Liberty Medical University invited talk 2019

Students trained

Kelly Guyton- PhD, 1997-2002 co-mentor Medical University of South Carolina.
Dimple Joshi- Phlebotomist summer training program MUSC. 2000
Jhenquan Jia Veterinary Medical Sciences (Virginia Tech) committee member PhD (2003-2006)
Steven Christofakis (mentor) University of Mary Washington (UMW) Biology Major; BBSI Program (Bioinformatics Bioengineering Summer Institute) 2007
Jason Romesburg: (mentor) DO worked as a medical student in my laboratory. He finished his degree at VCOM in 2007 and is now in residency at Wake Forest in interventional radiology.
David Goodwin: 2003-2006 (mentor) David was an undergraduate student in my laboratory. David is completed his Ph.D. in 2012.

Amjed Mustafa: (Co-mentor, PhD student 2004-2009), Virginia Maryland College of Veterinary Medicine, department of Biomedical Sciences and Pathobiology.

Ali Radjavi: (mentor) 2005-2008 -undergraduate student in my laboratory. Ali is currently a graduate student at UVA.

Julie Swenson: (mentor) 2006-2007 mentor, Julie is a received her DVM from the VMRCVM, was a research intern in my laboratory. Julie was primary author on a manuscript is currently a veterinarian in Tempe, Arizona.

Rachel Edelstein: (mentor) 2006-2009 was an undergraduate student in my laboratory. Rachel became a technician at Harvard Medical School in the laboratory of Dr. Michael Lawlor.

Kristina Cocco: (mentor) 2008-2009 was an undergraduate student in my laboratory. Kristina completed graduate school at Virginia Commonwealth University.

Megan Thomas: (mentor) 2006-2009 was an undergraduate student in my laboratory. Megan co authored a manuscript and presented at FASEB in 2008. Megan completed veterinary school at VMRCVM.

Suzanne Hirst (mentor) Veterinary Medical Sciences (VMRCVM) Maters student (2008-2010). Suzanne was also an undergraduate student (2006-2008) in my laboratory She is currently a Physician's Assistant in Oregon.

Samuel Shimp (co-mentor 2008-2012 PhD awarded) biomedical engineering at VT.

Cristen Chafin (mentor 2008-2013 PhD awarded). Cristen was a graduate student in Biomedical Sciences and Pathobiology at the veterinary school. She won multiple awards for her research as a student.

Nicole Regna (mentor 2008-2014 PhD awarded). Nicole was a graduate student in Biomedical Sciences and Pathobiology at the veterinary school. She won multiple awards for her research as a student.

Adrian Castanda (mentor 2014-2016). Adrian graduated with his Mater's degree in 2016

Miranda Vieson (mentor 2012-2016 PhD awarded). Miranda was a graduate student in Biomedical Sciences and Pathobiology at the veterinary school.

Jinjing Ren (mentor 2015-2019 PhD awarded). Jingjing was a graduate student in Biomedical Sciences and Pathobiology at the veterinary school.

NIH T-35 Summer Veterinary Student Research Program VMRCVM

Krystina Eden (mentor) Veterinary student at VMRCVM. Krystina completed a research project in my laboratory summer 2008 and is currently a third year veterinary student.

Paul Listrone (mentor) Veterinary student at VMRCVM. Paul completed a research project in my laboratory summer 2007 (currently a 4th year veterinary student).

Multicultural Academic Outreach Program

Trained two students in the summer of 2010 from Elizabeth City State University (ECSU); Valerie Smith and Carol Parsons are both seniors at ECSU.

Current Graduate students

Dao Xu (mentor 2020-present) Dao is currently a PhD candidate in in Biomedical Sciences and Pathobiology at the veterinary school.

Committees

Postdoctoral association Steering committee Medical University of South Carolina 1998-2000

Internal Review Board, Virginia College of Osteopathic Medicine 2002-present

Internal Review committee, Virginia College of Osteopathic Medicine 2002-2003

Appointment and tenure committee VCOM 2012-present

Promotion board VCOM 2012-present

Via Wellness Committee, Virginia College of Osteopathic Medicine 2002-2008
Library committee VCOM 2021-present
Arthritis Foundation Board of Directors (Carolina Chapter) 2000-2002
Faculty handbook taskforce VCOM 2005-2006
Special Olympics Board of Directors for the New River Valley 2005-2102

Publications

1. Mills, T. M., **C. M. Reilly**, and R. W. Lewis. 1996. Androgens and penile erection: a review. *Journal of Andrology* 17:633-638.
2. Mills, T. M., V. S. Stopper, and **C. M. Reilly**. 1996. Sites of androgenic regulation of cavernosal blood pressure during penile erection in the rat. *International Journal of Impotence Research* 8:29-34.
3. **Reilly, C. M.**, W. E. Cannady, V. B. Mahesh, V. S. Stopper, L. M. De Sevilla, and T. M. Mills. 1996. Duration of estrogen exposure prior to follicle-stimulating hormone stimulation is critical to granulosa cell growth and differentiation in rats. *Biol Reprod* 54:1336-1342.
4. **Reilly, C. M.**, R. W. Lewis, V. S. Stopper, and T. M. Mills. 1997. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. *Journal of Andrology* 18:588-594.
5. **Reilly, C. M.**, P. Zamorano, V. S. Stopper, and T. M. Mills. 1997. Androgenic regulation of NO availability in rat penile erection [see comments]. *Journal of Andrology* 18:110-115.
6. **Reilly, C. M.**, V. S. Stopper, and T. M. Mills. 1997. Androgens modulate the alpha-adrenergic responsiveness of vascular smooth muscle in the corpus cavernosum. *Journal of Andrology* 18:26-31.
7. **Reilly, C. M.**, P. Zamorano, V. S. Stopper, and T. M. Mills. 1997. Androgenic regulation of NO availability in rat penile erection. *J Androl* 18:110-115.
8. Mills, T. M., R. W. Lewis, V. S. Stopper, and C. M. Reilly. 1998. The loss of alpha-adrenergic effect during the erectile response in the long-term diabetic rat. *Journal of Andrology* 19:473-478.
9. Gilkeson, G., C. Cannon, J. Oates, **C. Reilly**, D. Goldman, and M. Petri. 1999. Correlation of serum measures of nitric oxide production with lupus disease activity. *Journal of Rheumatology* 26:318-324.
10. Oates, J. C., E. F. Christensen, **C. M. Reilly**, S. E. Self, and G. S. Gilkeson. 1999. Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity. *Proceedings of the Association of American Physicians* 111:611-621.
11. Molano, I., S. Redmond, H. Sekine, J. Zhang, **Reilly, C. M.** and G. Gilkeson. 2000. Genetic and pharmacologic blockade of TdT modulates autoantibody production, renal disease and survival in MRL/lpr mice. *Arthritis and Rheumatism* 43:s93.
12. **Reilly, C. M.**, J. C. Oates, J. A. Cook, J. D. Morrow, P. V. Halushka, and G. S. Gilkeson. 2000. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J(2) and proliferator activation receptor-gamma agonists. *Journal of Immunology*. 164:1498-1504.
13. Guyton, K., R. Bond, **C. Reilly**, G. Gilkeson, P. Halushka, and J. Cook. 2001. Differential effects of 15-deoxy-delta(12,14)-prostaglandin J2 and a peroxisome proliferator-activated receptor gamma agonist on macrophage activation. *Journal of Leukocyte Biology* 69:631-638.
14. **Reilly, C. M.**, J. C. Oates, J. Sodian, M. B. Crosby, P. V. Halushka, and G. S. Gilkeson. 2001. Prostaglandin J(2) inhibition of mesangial cell iNOS expression. *Clinical Immunology* 98:337-345.
15. Sekine, H., **C. M. Reilly**, I. D. Molano, G. Garnier, A. Circolo, P. Ruiz, V. M. Holers, S. A. Boackle, and G. S. Gilkeson. 2001. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. *Journal of Immunology* 166:6444-6451.
16. Oates, J. C., **C. M. Reilly**, M. B. Crosby, and G. S. Gilkeson. 2002. Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases. *Arthritis & Rheumatism* 46:598-605.

17. **Reilly, C. M.**, and G. S. Gilkeson. 2002. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. *Immunologic Research* 25:143-153.
18. **Reilly, C. M.**, L. W. Farrelly, D. Viti, S. T. Redmond, F. Hutchison, P. Ruiz, P. Manning, J. Connor, and G. S. Gilkeson. 2002. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. *Kidney Int* 61:839-846.
19. Masuya, M., C. J. Drake, P. A. Fleming, **C. M. Reilly**, H. Zeng, W. D. Hill, A. Martin-Studdard, D. C. Hess, and M. Ogawa. 2003. Hematopoietic origin of glomerular mesangial cells. *Blood* 101:2215-2218.
20. Mishra, N., **C. M. Reilly**, D. R. Brown, P. Ruiz, and G. S. Gilkeson. 2003. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. *Journal of Clinical Investigation* 111:539-552.
21. Molano, I. D., S. Redmond, H. Sekine, X. K. Zhang, **C. Reilly**, F. Hutchison, P. Ruiz, and G. S. Gilkeson. 2003. Effect of genetic deficiency of terminal deoxynucleotidyl transferase on autoantibody production and renal disease in MRL/lpr mice. *Clin Immunol* 107:186-197.
22. Guyton, K., B. Zingarelli, S. Ashton, G. Teti, G. Tempel, **C. Reilly**, G. Gilkeson, P. Halushka, and J. Cook. 2003. Peroxisome proliferator-activated receptor-gamma agonists modulate macrophage activation by gram-negative and gram-positive bacterial stimuli. *Shock* 20:56-62.
23. **Reilly, C. M.**, N. Mishra, J. M. Miller, D. Joshi, P. Ruiz, V. M. Richon, P. A. Marks, and G. S. Gilkeson. 2004. Modulation of renal disease in MRL/lpr mice by suberoylanilide hydroxamic acid. *J Immunol* 173:4171-4178.
24. Douglas, G., **C. Reilly**, M. A. Dooley, G. Page, G. Cooper, and G. Gilkeson. 2004. Angiotensin-converting enzyme (insertion/deletion) and endothelial nitric oxide synthase polymorphisms in patients with systemic lupus erythematosus. *J Rheumatol* 31:1756-1762.
25. Klein, A. B., S. G. Witonsky, S. A. Ahmed, S. D. Holladay, R. M. Gogal, Jr., L. Link, and **C. M. Reilly**. 2006. Impact of different cell isolation techniques on lymphocyte viability and function. *J Immunoassay Immunochem* 27:61-76.
26. **Reilly, C. M.**, S. Olgun, D. Goodwin, R. M. Gogal, Jr., A. Santo, J. W. Romesburg, S. A. Ahmed, and G. S. Gilkeson. 2006. Interferon regulatory factor-1 gene deletion decreases glomerulonephritis in MRL/lpr mice. *Eur J Immunol* 36:1296-1308.
27. Swenson, J., S. Olgun, A. Radjavi, T. Kaur, and **C. M. Reilly**. 2007. Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice. *Eur J Pharmacol* 567:67-76.
28. Strobl, J. S., M. Cassell, S. M. Mitchell, **C. M. Reilly**, and D. S. Lindsay. 2007. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. *J Parasitol* 93:694-700.
29. **Reilly, C. M.**, M. Thomas, R. Gogal, Jr., S. Olgun, A. Santo, R. Sodhi, E. T. Samy, S. L. Peng, G. S. Gilkeson, and N. Mishra. 2008. The histone deacetylase inhibitor trichostatin A upregulates regulatory T cells and modulates autoimmunity in NZB/W F1 mice. *J Autoimmun* 31:123-130.
30. Mustafa, A., S. D. Holladay, M. Goff, S. G. Witonsky, R. Kerr, **C. M. Reilly**, D. P. Sponenberg, and R. M. Gogal, Jr. 2008. An enhanced postnatal autoimmune profile in 24 week-old C57BL/6 mice developmentally exposed to TCDD. *Toxicol Appl Pharmacol* 232:51-59.
31. Vincent, A., S. Babu, E. Heckert, J. Dowding, S. M. Hirst, T. M. Inerbaev, W. T. Self, **C. M. Reilly**, A. E. Masunov, T. S. Rahman, and S. Seal. 2009. Protonated Nanoparticle Surface Governing Ligand Tethering and Cellular Targeting. *ACS Nano*.
32. Peairs, A., A. Radjavi, S. Davis, L. Li, A. Ahmed, S. Giri, and **C. M. Reilly**. 2009. Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells. *Clin Exp Immunol* 156:542-551.
33. Hirst, S. M., A. S. Karakoti, R. D. Tyler, N. Sriranganathan, S. Seal, and C. M. Reilly. 2009. Anti-inflammatory properties of cerium oxide nanoparticles. *Small* 5:2848-2856.
34. Mustafa, A., S. D. Holladay, S. Witonsky, K. Zimmerman, **C. M. Reilly**, D. P. Sponenberg, D. A. Weinstein, E. Karpuzoglu, and R. M. Gogal, Jr. 2009. Gestational exposure to 2,3,7,8-

- tetrachlorodibenzo-p-dioxin disrupts B-cell lymphopoiesis and exacerbates autoimmune disease in 24-week-old SNF1 mice. *Toxicol Sci* 112:133-143.
35. Maitra, U., S. Davis, **C. M. Reilly**, and L. Li. 2009. Differential regulation of Foxp3 and IL-17 expression in CD4 T helper cells by IRAK-1. *J Immunol* 182:5763-5769.
 36. Peairs, A., R. Dai, L. Gan, S. Shimp, M. N. Rylander, L. Li, and **C. M. Reilly**. 2010. Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. *Cell Mol Immunol*.
 37. Chafin, C., S. Muse, R. Hontecillas, Bassaganya-Riera, D. Caudell, S. Shimp, M. Rylander, L. Li, and **C. Reilly**. 2010. Deletion of PPAR- γ in immune cells enhances susceptibility to antglomerular basement membrane disease. *The Journal of Inflammation Research* 3:127-134.
 38. Peairs, A., R. Dai, L. Gan, S. Shimp, M. N. Rylander, L. Li, and **C. M. Reilly**. 2010. Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells. *Cell Mol Immunol* 7:123-132.
 39. **Reilly, C. M.**, N. Regna, and N. Mishra. 2011. HDAC Inhibition in Lupus Models. *Mol Med* 17:417-425.
 40. Alili, L., M. Sack, A. S. Karakoti, S. Teuber, K. Puschmann, S. M. Hirst, **C. M. Reilly**, K. Zanger, W. Stahl, S. Das, S. Seal, and P. Brenneisen. 2011. Combined cytotoxic and anti-invasive properties of redox-active nanoparticles in tumor-stroma interactions. *Biomaterials* 32:2918-2929.
 41. Yan, K., Q. Cao, **C. M. Reilly**, N. L. Young, B. A. Garcia, and N. Mishra. 2011. Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. *J Biol Chem* 286:28833-28843.
 42. Hirst, S. M., A. Karakoti, S. Singh, W. Self, R. Tyler, S. Seal, and **C. M. Reilly**. 2011. Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. *Environ Toxicol* 28:107-118.
 43. Puthiyaveetil, A. G., B. Heid, **C. M. Reilly**, H. HogenEsch, and D. L. Caudell. 2012. A NUP98-HOXD13 leukemic fusion gene leads to impaired class switch recombination and antibody production. *Exp Hematol* 40:622-633.
 44. Shimp, S. K., 3rd, C. B. Chafin, N. L. Regna, S. E. Hammond, M. A. Read, D. L. Caudell, M. Rylander, and **C. M. Reilly**. 2012. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. *Cell Mol Immunol* 9:255-266.
 45. Shimp, S. K., 3rd, C. D. Parson, N. L. Regna, A. N. Thomas, C. B. Chafin, **C. M. Reilly**, and M. Nichole Rylander. 2012. HSP90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-kappaB pathways. *Inflamm Res* 61:521-533.
 46. Puthiyaveetil, A. G., B. Okyere, **C. M. Reilly**, and D. Caudell. 2013. Diverging in vitro antibody isotype switching preference in B-lymphocytes from C57BL/6 and FVB mice. *In Vivo* 27:29-39.
 47. Chafin, C. B., N. L. Regna, R. Dai, D. L. Caudell, and **C. M. Reilly**. 2013. MicroRNA-let-7a expression is increased in the mesangial cells of NZB/W mice and increases IL-6 production in vitro. *Autoimmunity* 46:351-362.
 48. Chafin, C. B., and **C. M. Reilly**. 2013. MicroRNAs Implicated in the Immunopathogenesis of Lupus Nephritis. *Clin Dev Immunol* 2013:430239.
 49. Schanen, B. C., S. Das, **C. M. Reilly**, W. L. Warren, W. T. Self, S. Seal, and D. R. Drake, 3rd. 2013. Immunomodulation and T helper TH(1)/TH(2) response polarization by CeO(2) and TiO(2) nanoparticles. *PLoS One* 8:e62816.
 50. Wong, L. L., S. M. Hirst, Q. N. Pye, **C. M. Reilly**, S. Seal, and J. F. McGinnis. 2013. Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection. *PLoS One* 8:e58431.
 51. Giri, S., A. Karakoti, R. P. Graham, J. L. Maguire, **C. M. Reilly**, S. Seal, R. Rattan, and V. Shridhar. 2013. Nanoceria: a rare-earth nanoparticle as a novel anti-angiogenic therapeutic agent in ovarian cancer. *PLoS One* 8:e54578.

52. Puthiyaveetil, A. G., **C. M. Reilly**, T. S. Pardee, and D. L. Caudell. 2013. Non-homologous end joining mediated DNA repair is impaired in the NUP98-HOXD13 mouse model for myelodysplastic syndrome. *Leuk Res* 37:112-116.
53. Parson C, Smith V, Krauss C, Banerjee HN, **Reilly C**, Krause JA, Wachira JM, Giri D, Winstead A, Mandal SK. The effect of novel rhenium compounds on lymphosarcoma, PC-3 prostate and myeloid leukemia cancer cell lines and an investigation on the DNA binding properties of one of these compounds through electronic spectroscopy. *J Bioprocess Biotech.* 2013 Dec 27;4(1):141.PMID: 25221731
54. Bandara, SM Boyle, A Contreras-Rodriguez, AM Martins, R Prasad, and **C. M. Reilly**. *Brucella melitensis* Differs from *B. suis* in Growth and Urease Activity in Vitro, and Infectivity in Fisher-344 Rats in Vivo *Advances in Infectious Diseases*, 2013, 60-62.
55. Chafin, C.B., Regna, N.L., Caudell, D.L., and **Reilly, C.M.** MicroRNA-let-7a promotes NFκB activation and E2F-mediated cell proliferation in vitro. *Cell Mol Immunol.* 2014 Jan;11(1):79-83PMID:24240124
56. Chafin, C.B., Regna, N.L., Hammond, S.E., Caudell, D.L., and **Reilly, C.M.** Cellular and urinary microRNA alterations in NZB/W mice with hydroxychloroquine or prednisone treatment. *Int Immunopharmacol.* 2013 Nov;17(3):894-906.PMID: 24121037
57. Regna LN, Chafin CB, Hammond SE, Puthiyaveetil AG, Caudell, DL, and **Reilly CM.** Class I and II Histone Deacetylase Inhibition by ITF2357 Reduces SLE Pathogenesis In Vivo. *Clin Immunol.* 2014 Mar;151(1):29-42. PMID:24503172
58. Regna LN and Reilly CM. Isoform-Selective HDAC Inhibition in Autoimmune Disease. *J Clin Cell Immunol* 5:207. 2014
59. Regna NL, Vieson MD, Luo XM, Chafin CB, Puthiyaveetil AG, Hammond SE, Caudell DL, Jarpe MB, **Reilly CM.** Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. *Clin Immunol.* 2016 Jan;162:58-73. doi: 10.1016/j.clim.2015.11.007. Epub 2015 Nov 22. PMID:26604012
60. Parson C, Smith V, Krauss C, Banerjee HN, **Reilly C**, Krause JA, Wachira JM, Giri D, Winstead A, Mandal SK. Anticancer Properties of Novel Rhenium Pentylcarbanato Compounds against MDA-MB-468(HTB-132) Triple Node Negative Human Breast Cancer Cell Lines. *Br J Pharm Res.* 2015 Feb 1;4(3):362-367. PMID:25419517
61. Regna NL, Vieson MD, Gojmerac AM, Luo XM, Caudell DL, **Reilly CM.** HDAC expression and activity is upregulated in diseased lupus-prone mice. *Int Immunopharmacol.* 2015 Dec;29(2):494-503. doi: 10.1016/j.intimp.2015.10.006. Epub 2015 Oct 21. PMID: 26471208
62. Liao X, Li S, Settlage RE, Sun S, Ren J, Reihl AM, Zhang H, Karyala SV, **Reilly CM**, Ahmed SA, Luo XM. Cutting Edge: Plasmacytoid Dendritic Cells in Late-Stage Lupus Mice Defective in Producing IFN-α. *J Immunol.* 2015 Nov 15;195(10):4578-82. doi: 10.4049/jimmunol.1501157. Epub 2015 Oct 7. PMID: 26447229
63. Regna NL, Vieson MD, Gojmerac AM, Luo XM, Caudell DL, **Reilly CM.** HDAC expression and activity is upregulated in diseased lupus-prone mice. *International immunopharmacology.* 2015; 29(2):494-503. NIHMSID: NIHMS730695 PubMed [journal] PMID: 26471208, PMCID: PMC466673
64. Regna NL, Vieson MD, Luo XM, Chafin CB, Puthiyaveetil AG, Hammond SE, Caudell DL, Jarpe MB, **Reilly CM.** Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice. *Clinical immunology (Orlando, Fla.).* 2016; 162:58-73. PubMed [journal] PMID: 26604012
65. Mu Q, Zhang H, Liao X, Lin K, Liu H, Edwards MR, Ahmed SA, Yuan R, Li L, Cecere TE, Branson DB, Kirby JL, Goswami P, Leeth CM, Read KA, Oestreich KJ, Vieson MD,

- Reilly CM**, Luo XM. Control of lupus nephritis by changes of gut microbiota. *Microbiome*. 2017; 5(1):73. PubMed [journal] PMID: 28697806, PMCID: PMC5505136
66. Mu Q, Tavella VJ, Kirby JL, Cecere TE, Chung M, Lee J, Li S, Ahmed SA, Eden K, Allen IC, **Reilly CM**, Luo XM. Antibiotics ameliorate lupus-like symptoms in mice. *Scientific reports*. 2017; 7(1):13675. PubMed [journal] PMID: 29057975, PMCID: PMC5651817
67. Liao X, Ren J, Reihl A, Pirapakaran T, Sreekumar B, Cecere TE, **Reilly CM**, Luo XM. Renal-infiltrating CD11 cells are pathogenic in murine lupus nephritis through promoting CD4⁺ T cell responses. *Clinical and experimental immunology*. 2017; 190(2):187-200. PubMed [journal] PMID: 28722110, PMCID: PMC5629427
68. Ren J, Liao X, Vieson MD, Chen M, Scott R, Kazmierczak J, Luo XM, **Reilly CM**. Selective HDAC6 inhibition decreases early stage of lupus nephritis by down-regulating both innate and adaptive immune responses. *Clinical and experimental immunology*. 2018; 191(1):19-31. PubMed [journal] PMID: 28876451, PMCID: PMC5721231
69. Luo XM, Edwards MR, Mu Q, Yu Y, Vieson MD, **Reilly CM**, Ahmed SA, Bankole AA. Gut Microbiota in Human Systemic Lupus Erythematosus and a Mouse Model of Lupus. *Applied and environmental microbiology*. 2018; 84(4). PubMed [journal] PMID: 29196292, PMCID: PMC5795066
70. Ren J, Panther E, Liao X, Grammer AC, Lipsky PE, **Reilly CM**. The Impact of Protein Acetylation/Deacetylation on Systemic Lupus Erythematosus. *International journal of molecular sciences*. 2018; 19(12). PubMed [journal] PMID: 30545086, PMCID: PMC6321219
71. Ren J, Catalina MD, Eden K, Liao X, Read KA, Luo X, McMillan RP, Hulver MW, Jarpe M, Bachali P, Grammer AC, Lipsky PE, **Reilly CM** Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus. *Front Immunol*. 2019 Oct 25;10:2512. doi: 10.3389/fimmu.2019.02512. eCollection 2019. PMID: 31708928
72. Mu Q, Cabana-Puig X, Mao J, Swartwout B, Abdelhamid L, Cecere TE, Wang H, **Reilly CM**, Luo XM. Pregnancy and lactation interfere with the response of autoimmunity to modulation of gut microbiota. *Microbiome*. 2019 Jul 16;7(1):105. doi: 10.1186/s40168-019-0720-8 PMID: 31311609
73. Eric Panther, Xavier Cabana Puig, Jingjing Ren, Xiaofeng Liao, Brianna Swartwout, Miranda Vieson, Leila Abdelhamid, Ashton Shiraz, Xin Luo, Christopher M. Reilly. The Effect of Dietary Fiber Intake on Systemic Lupus Erythematosus (SLE) Disease in NZB/W Lupus Mice. 2020 *J Clin Cell Immunol*, Vol.11 Iss.3 No:1000590
74. Dai R, Heid B, Xu X, Xie H, **Reilly CM**, Ahmed SA EGR2 is elevated and positively regulates inflammatory IFN γ production in lupus CD4⁺ T cells. *BMC Immunol*. 2020 Jul 9;21(1):41. doi: 10.1186/s12865-020-00370-z. PMID: 32646370
75. Abdelhamid L, Cabana-Puig X, Swartwout B, Lee J, Li S, Sun S, Li Y, Ross AC, Cecere TE, LeRoith T, Werre SR, Wang H, **Reilly CM**, Luo XM. Retinoic Acid Exerts Disease Stage-Dependent Effects on Pristane-Induced Lupus. *Front Immunol*. 2020 Mar 20;11:408. doi: 10.3389/fimmu.2020.00408. eCollection 2020. PMID: 32265909
76. Mu Q, Edwards MR, Swartwout BK, Cabana Puig X, Mao J, Zhu J, Grieco J, Cecere TE, Prakash M, **Reilly CM**, Puglisi C, Bachali P, Grammer AC, Lipsky PE, Luo XM. Front Gut Microbiota and Bacterial DNA Suppress Autoimmunity by Stimulating Regulatory B Cells in a Murine Model of Lupus. *Immunol*. 2020 Nov 10;11:593353. doi: 10.3389/fimmu.2020.593353. eCollection 2020. PMID: 33240280

77. Cabana-Puig X, Bond JM, Wang Z, Dai R, Lu R, Lin A, Oakes V, Rizzo A, Swartwout B, Abdelhamid L, Mao J, Prakash M, Sangmeister C, Cheung N, Cowan C, **Reilly CM**, Sun S, Ahmed SA, Luo XM. Phenotypic Drift in Lupus-Prone MRL/lpr Mice: Potential Roles of MicroRNAs and Gut Microbiota. *Immunohorizons*. 2022 Jan 17;6(1):36-46. doi: 10.4049/immunohorizons.2100082.PMID: 35039434
78. Mu Q, Swartwout BK, Edwards M, Zhu J, Lee G, Eden K, Cabana-Puig X, McDaniel DK, Mao J, Abdelhamid L, Brock RM, Allen IC, **Reilly CM**, Luo XM. Regulation of neonatal IgA production by the maternal microbiota. *Proceeding of Natl Acad Sci U S A*. 2021 Mar 2;118(9):e2015691118. doi: 10.1073/pnas.2015691118.PMID: 33619092
79. Shiraz AK, Panther EJ, **Reilly CM**. Altered Germinal-Center Metabolism in B Cells in Autoimmunity. *Metabolites*. 2022 Jan 5;12(1):40. doi: 10.3390/metabo12010040.PMID: 35050162

A complete list of my 79 peer reviewed publications can be found at:

<https://www.ncbi.nlm.nih.gov/sites/myncbi/1jefe-5wb2pk8/bibliography/45795288/public/?sort=date&direction=descending>

Other interests

Have organized and been the race director for several national Triathlons and running events

Compete in triathlons and running events

Director of Aquatics for the Special Olympics in Blacksburg, VA

Volunteer for the Arthritis Foundation

Head Swim Coach for Blacksburg High School men's and woman's swim team

Nationally Certificated USA swimming official